The Investment Case

Long-acting drug delivery creates value where oral regimens fail: poor adherence, exposure variability, regimen complexity, or structural barriers to treatment completion. These failure modes recur across therapeutic areas and patient populations. Extentus applies a single productisation framework: candidate selection, formulation development, translational PK, and diligence packaging to each programme in sequence.

LAI Abiraterone is the portfolio’s strongest near-term candidate. Abiraterone is guideline-recommended across metastatic prostate cancer, with a well-characterised exposure-response relationship and a documented adherence problem driven by the oral formulation’s fasting requirement and exposure variability. A long-acting injectable could address both. The 505(b)(2) pathway may support an approval strategy built on PK bridging, potentially reducing the scope of confirmatory clinical work.

Development spend is concentrated at the formulation, translational PK, and clinical proof-of-concept stages, the inflexion points that drive transaction value. Late-stage confirmatory work and commercial execution are structured for partner or acquirer engagement. Much of the portfolio beyond the lead asset advances through external grant funding, adding platform optionality.

Long-acting formulations command a commercial premium where adherence failure has a measurable clinical consequence, and the delivery advantage can be demonstrated against an oral comparator. Extentus programmes are selected where this case is strongest. The company is building towards a trade sale, licensing transaction, or strategic partnership, with the portfolio structured to generate multiple transaction opportunities from the same platform. The long-acting delivery sector has shown consistent strategic demand, with acquirers and licensing partners paying material premiums for validated platforms with repeatable output.

Extentus Pharma was spun out of the University of Liverpool and is led by a team spanning drug delivery science, pharmacology, regulatory strategy, and pharmaceutical commercialisation. Backed by investors experienced in early-stage pharmaceutical and life-sciences development, the company is actively engaged in a fundraising process to advance its lead programmes to clinical proof of concept.